{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:08:19Z","timestamp":1783750099363,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.therap.2020.11.003","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T12:25:25Z","timestamp":1605615925000},"page":"504-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vitiligo and anti-tumor necrosis factors: Cases report"],"prefix":"10.1016","volume":"76","author":[{"given":"Nada","family":"Jaouad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawther","family":"Ben Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Sellami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadoua","family":"Khadiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"Amine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Elbinoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Fazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Laatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-1750","authenticated-orcid":false,"given":"Rachid","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.11.003_bib0055","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/03009740902922612","article-title":"Immune-mediated skin lesions in patients treated with antitumor necrosis factor alpha inhibitors","volume":"38","author":"Exarchou","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.therap.2020.11.003_bib0060","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-4632.2006.02744.x","article-title":"Increased tumour necrosis factor alpha (TNF-\u03b1) and interleukin 1 alpha (IL-1a) levels in the lesional skin of patients with nonsegmental vitiligo","volume":"45","author":"Birol","year":"2006","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.therap.2020.11.003_bib0065","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study","volume":"38","author":"Bae","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.therap.2020.11.003_bib0070","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/imj.13498","article-title":"New onset vitiligo following commencement of infliximab in Crohn disease","volume":"47","author":"Raphael","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.therap.2020.11.003_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.11.003_bib0080","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance \u2014 The next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.therap.2020.11.003_bib0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjd.14016","article-title":"Tumor necrosis factor-a inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2020.11.003_bib0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/15569527.2011.560913","article-title":"Tumor necrosis factor in vitiligo: direct correlation between tissue levels and clinical parameters","volume":"30","author":"Kim","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.therap.2020.11.003_bib0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000112932","article-title":"Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab","volume":"216","author":"Simon","year":"2008","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.therap.2020.11.003_bib0100","first-page":"534","article-title":"Treatment of generalized vitiligo with anti-TNF-\u03b1 agents","volume":"11","author":"Alghamdi","year":"2012","journal-title":"J Drugs Dermatol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:35Z","timestamp":1758567275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720301967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0040595720301967"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.11.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo and anti-tumor necrosis factors: Cases report","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}